A Study of Cells in the Blood that may be Contributing to Allergic Inflammation in Asthmatics

Overview

Información sobre este estudio

The purpose of this study is to identify a new population of cells in the blood that may be contributing to allergic inflammation in atopic asthmatics.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Ages 18-75 years 

Normal Healthy Individuals

  • Healthy individuals with no history of asthma or allergy 
  • Normal spirometry   
  • Normal exhaled nitric oxide (eNO) test 
  • Blood eosinophils < 0.5 x 10 9 cells / L   
  • Negative skin prick test results or negative IgE serum tests to 10 common aeroallergens

Patients with Asthma with and without Nasal Polyps 

  • Asthma patients from the clinical practice of the Division of Allergic Diseases, Mayo Clinic Rochester 
  • The definition of asthma is based on the National Asthma Education and Prevention Program (NAEPP) 2007 Expert Panel Report  
  • Includes a physician’s determination that the subject’s history and physical examination are consistent with the diagnosis. 
  • Asthma patients have a history of variable airflow obstruction with at least 1 of the following:
    • Airway hyperreactivity (AHR)(PC20 methacholine ≤16 mg/ml) OR
    • A positive bronchodilator response (FEV1 change ≥12% following 2 puffs of albuterol (90 µg per puff) documented within the past 2 years. 

Exclusion Criteria

  • Received systemic glucocorticoids during the past 3 months
  • Previous (> 10 pack year smoking history) or current smokers
  • Lower or upper airway infection (eg. “cold”) in the last 4 weeks
  • Diagnosed with immunodeficiency, cystic fibrosis, or any other respiratory or general medical problem which in the investigator feels would preclude inclusion into the study e.g. infection, malignancy
  • Immunotherapy with any allergen
  • Pregnancy
  • Immunosuppressive medication

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Rochester, Minn.

Investigador principal de Mayo Clinic

Hirohito Kita, M.D.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available
.
CLS-20311804

Mayo Clinic Footer